You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
同源康醫藥(02410.HK)三款臨牀產品試驗結果獲ESMO以壁報形式收錄
同源康醫藥-B(02410.HK)公佈,公司自主研發的三款臨牀產品TY-302、TY-2699a及TY-0540的I期臨牀試驗結果,正式獲2025年歐洲腫瘤內科學會(ESMO)大會以壁報形式收錄。 其中,TY-302臨牀數據展現出顯着療效和良好安全性,後續臨牀研究持續開展中。初步臨牀數據顯示,TY-2699a在同類劑量水平下兼具優異安全性和初步療效。臨牀前和臨牀研究顯示,TY-0540在乳腺癌、卵巢癌等多種實體瘤中均展現出顯着抑制效果及良好安全性。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account